Pancreatic Cancer Research

ResearcherVan Andel InstituteActive in the last 2 years

Chanjuan Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5962-6479; OpenAlex author ID A5059525044. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
95
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 14

  1. Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples. Co-author DOI 10.1126/sciadv.adt0029↗
  2. Editor's Note: Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1304↗
  3. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  4. Heterogeneity of glycan biomarker clusters as an indicator of recurrence in pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1135405↗
  5. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  6. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  7. Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.26621↗
  8. Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-0579↗
  9. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-0634↗
  10. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model … Co-author DOI 10.1053/j.gastro.2015.07.058↗
  11. Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. Co-author DOI 10.1038/labinvest.2014.10↗
  12. Loss of HNF6 expression correlates with human pancreatic cancer progression. Co-author DOI 10.1038/labinvest.2014.47↗
  13. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Co-author DOI 10.5858/arpa.2013-0056-oa↗
  14. Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma. Last author PMID 24228110↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nipun B. Merchant · 8 shared papers, 2013–2025 · strength 0.68
  2. Jason A. Castellanos · 5 shared papers, 2015–2025 · strength 0.54
  3. Nagaraj S. Nagathihalli · 5 shared papers, 2015–2025 · strength 0.54
  4. Peter J. Allen · 3 shared papers, 2023–2025 · strength 0.54
  5. Michael Nathan VanSaun · 4 shared papers, 2018–2025 · strength 0.50
  6. ChongFeng Gao · 2 shared papers, 2023–2025 · strength 0.40
  7. Brian B. Haab · 2 shared papers, 2023–2025 · strength 0.40
  8. Aatur Dilip Singhi · 3 shared papers, 2021–2025 · strength 0.39
  9. Marc G. Besselink · 3 shared papers, 2021–2024 · strength 0.32
  10. Xi Chen · 1 shared paper, 2025 · strength 0.25
  11. Luke Wisniewski · 1 shared paper, 2023 · strength 0.20
  12. Braelyn Binkowski · 1 shared paper, 2025 · strength 0.20
  13. Ben Staal · 1 shared paper, 2025 · strength 0.20
  14. Randall E. Brand · 1 shared paper, 2025 · strength 0.20
  15. Steve Gallinger · 1 shared paper, 2025 · strength 0.20
  16. Ying Huang · 1 shared paper, 2025 · strength 0.20
  17. Olca Baştürk · 2 shared papers, 2021–2022 · strength 0.19
  18. Boris V. Janssen · 2 shared papers, 2021–2022 · strength 0.19
  19. Volkan N. Adsay · 2 shared papers, 2021–2022 · strength 0.19
  20. Huamin Wang · 2 shared papers, 2021–2022 · strength 0.19
  21. Stijn R. van Roessel · 2 shared papers, 2021–2022 · strength 0.19
  22. Noriyoshi Fukushima · 2 shared papers, 2021–2022 · strength 0.19
  23. Claudio Doglioni · 2 shared papers, 2021–2022 · strength 0.19
  24. Seung‐Mo Hong · 2 shared papers, 2021–2022 · strength 0.19
  25. Anthony James Gill · 2 shared papers, 2021–2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.